DexCom, Inc. (DXCM) Stock Price & Analysis
DexCom, Inc. (DXCM) closed at USD 79.93 on Thursday, October 29, 2026, up 1.67% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 78.62; the Oct 29, 2026 session ranged USD 78.59–80.01 on volume of 5,906,467 shares. Market capitalization is $30.16B, with a 52-week range of USD 54.11–92.59 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:57 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DXCM.md
Latest Earnings Results (DXCM)
DexCom, Inc. (DXCM) reported Q3 2026 results on Oct 29, 2026, 4:03:50 PM ET: adjusted EPS $0.73 vs. estimate $0.67 (beat), revenue $1.34B vs. estimate $1.33B (beat). Guidance: Dexcom raised its full-year 2026 revenue guidance to $5.20 - $5.25 billion. Source: SEC 8-K filing. Nexqual published it 43 seconds after release. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $0.73 (adjusted (non-GAAP) diluted) | $1.34B | Oct 29, 2026, 4:03:50 PM ET · on Nexqual +43 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (DXCM)
- Last four reported quarters (through Jun 30, 2026): revenue $4.97B, net income $1000M (20.1% margin), free cash flow $1.41B (SEC filings).
- Valuation: P/E 30.2x (avg 61.8x at the last 3 fiscal year-ends), EV/EBITDA 21.1x, net cash $567M.
- Insider open-market sales, last ~7 months: 21 Form 4 filings, $12.3M; 0 not under a Rule 10b5-1 plan ($0K); 10 by opportunistic insiders (0 outside 10b5-1 plans), 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.97 on a 1–5 scale) (29 analysts), mean target USD 96.19 (range 79–115).
- Total return with dividends: 1Y +17.2% vs S&P 500 +14.4%; 5Y -48.7% vs S&P 500 +79.1%.
- Next earnings: 2026-10-29, EPS estimate USD 0.67, revenue estimate $1.33B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DXCM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B | $4.97B |
| Gross profit | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B | — |
| Operating income | $266M | $391M | $598M | $600M | $912M | $1.14B |
| Net income | $217M | $341M | $542M | $576M | $836M | $1000M |
| EPS (diluted) | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 | — |
| Free cash flow | $53.3M | $305M | $512M | $631M | $1.08B | $1.41B |
| Gross margin | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% | — |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% | 22.9% |
| Net margin | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% | 20.1% |
| Revenue growth | +27.1% | +18.8% | +24.5% | +11.3% | +15.6% | — |
| Cash + short-term investments | $2.41B | $2.45B | $2.73B | $2.34B | $2.00B | — |
| Total debt | $1.98B | $1.20B | $2.43B | $1.24B | $1.24B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DXCM)
P/E 30.2x · P/S 6.1x · EV/EBITDA 21.1x · EV/Sales 6.0x · P/FCF 21.5x · P/B 11.5x · FCF yield 4.66% · Earnings yield 3.31% · Net cash $567M · EV $29.6B
P/E at fiscal year-ends: Dec 2025 32.2x, Dec 2024 55.7x, Dec 2023 97.5x.
Insider sales (SEC Form 4, open-market, last ~7 months) (DXCM)
21 of 21 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | Stern Sadie | EVP Chief People & Culture Off | 2,565 | $202K | 2.1% | Yes | Routine (sold in Mar & Jun each year 2023–2025; this trade is outside those months) |
| 2026-10-15 | Brown Michael Jon | EVP Chief Legal Compliance Off | 1,700 | $145K | 1.7% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-09-28 | Stern Sadie | EVP Chief People & Culture Off | 2,565 | $221K | 2% | Yes | Routine (sold in Mar & Jun each year 2023–2025; this trade is outside those months) |
| 2026-09-14…2026-09-15 | Augustinos Nicholas | Director | 8,089 | $680K | 18.8% | Yes | Too little history (no open-market trades in 2024) |
| 2026-09-15 | Brown Michael Jon | EVP Chief Legal Compliance Off | 1,700 | $143K | 1.7% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-09-10 | Sylvain Jereme M | EVP, Chief Financal Officer | 3,638 | $303K | 2.4% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-27 | Stern Sadie | EVP Chief People & Culture Off | 2,565 | $227K | 2% | Yes | Routine (sold in Mar & Jun each year 2023–2025; this trade is outside those months) |
| 2026-08-20 | Sayer Kevin R | Executive Chair | 26,756 | $2.4M | 8.1% | Yes | Routine (sold in Jan & Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-14 | Brown Michael Jon | EVP Chief Legal Compliance Off | 1,700 | $156K | 1.6% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-12 | Heller Bridgette P | Director | 1,012 | $89K | 3.3% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-31…2026-08-03 | Foletta Mark G | Director | 4,000 | $331K | 6.8% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-20 | Sayer Kevin R | Executive Chair | 26,756 | $2.0M | 7.5% | Yes | Routine (sold in Jan & Mar each year 2023–2025; this trade is outside those months) |
| 2026-07-15 | Brown Michael Jon | EVP Chief Legal Compliance Off | 1,700 | $127K | 1.6% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-06 | Sayer Kevin R | Executive Chair | 26,756 | $1.9M | 7% | Yes | Routine (sold in Jan & Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-15 | Brown Michael Jon | EVP Chief Legal Compliance Off | 1,700 | $128K | 1.6% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-15 | Foletta Mark G | Director | 4,000 | $297K | 6.3% | Yes | Too little history (no open-market trades in 2023) |
| 2026-06-03…2026-06-04 | Coleman Jon | EVP, Chief Commercial Officer | 9,823 | $723K | 9.3% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-21 | Sayer Kevin R | Executive Chair | 26,759 | $1.9M | 6.5% | Yes | Routine (sold in Jan & Mar each year 2023–2025; this trade is outside those months) |
| 2026-05-15 | Brown Michael Jon | EVP, Chief Legal Officer | 1,700 | $102K | 1.5% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-12 | Heller Bridgette P | Director | 1,012 | $61K | 3.9% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DXCM)
Consensus Buy (mean 1.97 on a 1–5 scale), 29 analysts; mean target USD 96.19 (low 79, high 115).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Target raised | Buy | $90 → $96 |
| 2026-10-07 | Barclays | Initiated | Overweight | $115 |
| 2026-10-01 | RBC Capital | Target raised | Outperform | $90 → $105 |
| 2026-09-18 | Truist Securities | Target raised | Buy | $93 → $102 |
| 2026-09-18 | TD Cowen | Reiterated | Buy | $95 |
| 2026-08-04 | Argus Research | Target raised | Buy | $86 → $96 |
| 2026-08-03 | Canaccord Genuity | Target raised | Buy | $82 → $90 |
| 2026-07-31 | Citigroup | Target raised | Buy | $84 → $88 |
| 2026-07-31 | RBC Capital | Target raised | Outperform | $85 → $90 |
| 2026-07-31 | Mizuho | Target raised | Outperform | $90 → $95 |
| 2026-07-31 | JP Morgan | Target raised | Neutral | $65 → $82 |
| 2026-07-31 | Piper Sandler | Target raised | Overweight | $88 → $95 |
Total return (dividends reinvested) (DXCM)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +17.2% | -48.7% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +17.3% | -12.5% |
| Volatility (annualized) | 40.5% | 50.2% |
| Max drawdown | -22.6% (Feb 2026→Apr 2026) | -66.0% (Nov 2021→Nov 2025) |
DXCM earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jul 30, 2026 | Quarter ended Jun 30, 2026 | $0.70 | $0.61 | Beat +14.8% | +11.1% |
| Apr 30, 2026 | Quarter ended Mar 31, 2026 | $0.56 | $0.47 | Beat +19.1% | +6.6% |
| Feb 12, 2026 | Quarter ended Dec 31, 2025 | $0.68 | $0.65 | Beat +4.6% | +2.7% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $0.68 | $0.65 | Beat +4.6% | +4.2% |
| Oct 30, 2025 | Quarter ended Sep 30, 2025 | $0.61 | $0.57 | Beat +7.0% | -14.6% |
| Jul 30, 2025 | — | — | — | — | -9.6% |
| May 1, 2025 | — | — | — | — | +14.3% |
| Feb 13, 2025 | — | — | — | — | +6.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
DXCM recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 29, 2026 | 8-K | Quarterly results; Other material event “On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share ("Common Stock"), with a repurchase period ending no later than December 31, 2027 (the "Share Repurchase Program"). Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of…” |
| Sep 14, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On September 10, 2026, the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company") appointed Jereme Sylvain, the Company's EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with Mr. Sylvain's promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the "Offer Letter") providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75%…” |
| Sep 10, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On September 10, 2026, the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company"), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Mr. Boehnlein will hold office for a term expiring at the 2027 annual meeting of Dexcom's stockholders (the "2027 Annual Meeting"). The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation…” |
| Jul 30, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 30, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
DXCM revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $933.4M | 71.3% | +11.0% |
| International | $375.0M | 28.7% | +18.6% |
| Total revenue | $1.31B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DXCM suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Such | “Such incidents may impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our customers.” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name DXCM in their SEC reports
| Relationship to DXCM | Company | Filing | Sentence |
|---|---|---|---|
| partner | Beta Bionics, Inc. (BBNX) | 10-K Feb 24, 2026 | “Commercialization Agreement with DexCom, Inc.” |
DXCM customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (55%, 46%, 35%) of revenue, per the company's 10-K filed Feb 12, 2026. The company does not name them.
DXCM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.67 | $0.67 | +0.0% | $1.33B | 23 |
| Next quarter (ends Dec 2026) | $0.74 | $0.75 | -1.9% | $1.40B | 22 |
| Current fiscal year (ends Dec 2026) | $2.66 | $2.59 | +2.9% | $5.23B | 26 |
| Next fiscal year (ends Dec 2027) | $3.12 | $3.08 | +1.5% | $5.79B | 26 |
DXCM options: expected move
Options price a move of about ±9.2% (±$7.48) by Oct 30, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±8.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 1 | 218.6% | ±9.2% |
| Nov 6, 2026 | 8 | 84.8% | ±10.0% |
| Nov 13, 2026 | 15 | 75.0% | ±12.1% |
| Nov 20, 2026 | 22 | 60.4% | ±11.8% |
| Nov 27, 2026 | 29 | 52.0% | ±11.6% |
| Dec 4, 2026 | 36 | 44.6% | ±11.1% |
| Dec 11, 2026 | 43 | 46.7% | ±12.7% |
| Dec 18, 2026 | 50 | 44.1% | ±12.8% |
30-day implied volatility 50.6% vs 32.1% realized over the last 30 trading days. Put/call ratio (volume) 0.93. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 20:57 UTC)
| Price | USD 79.93 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 78.62 |
| Open | USD 79.08 |
| Day Range | USD 78.59 – 80.01 |
| 52-Week Range | USD 54.11 – 92.59 |
| Volume | 5,906,467 shares |
| Market Cap | $30.16B |
| Exchange | NMS |
Technical Analysis (DXCM)
Nexqual's technical model rates DXCM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 20:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.02 (neutral) |
| vs SMA50 | Below (USD 85.98) |
| MACD | -1.98 (negative) |
Analyst Ratings (DXCM)
Wall Street analysts rate DXCM "Buy" based on 29 analysts, with a mean price target of USD 96.19 (range USD 79–115), per Nexqual as of October 29, 2026 at 20:57 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 96.19 |
| High Target | USD 115 |
| Low Target | USD 79 |
| Buy / Hold / Sell | 26 / 3 / 0 |
Earnings (DXCM)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.67 |
| Revenue Estimate | $1.33B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.7 vs est 0.61 ▲ beat |
| 2026-03-31 | USD 0.56 vs est 0.47 ▲ beat |
| 2025-12-31 | USD 0.68 vs est 0.65 ▲ beat |
| 2025-09-30 | USD 0.61 vs est 0.57 ▲ beat |
Source: Nexqual, October 29, 2026 at 20:57 UTC.
Financials & Fundamentals (DXCM)
| Total Revenue | $4.97B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +13.10% |
| Gross Margin | +62.47% |
| Operating Margin | +24.33% |
| Profit Margin | +20.12% |
| ROE | +38.49% |
| Debt / Equity | 0.53 |
| Current Ratio | 1.73 |
| Total Cash | $1.95B |
| Total Debt | $1.40B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.41B (28.3% of revenue) |
Source: Nexqual, October 29, 2026 at 20:57 UTC.
Financial Health Score (DXCM)
Nexqual rates DexCom, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 20:57 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 23% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Solid — $1.81B cash and investments vs $1.24B debt (Jun 2026, SEC), net cash |
| Cash Flow | Strong — FCF $1.41B (last 4 quarters to Jun 2026, SEC), 28% margin |
| Efficiency | Strong — ROE 38%, ROA 15.5% (last 4 quarters, SEC) |
Ownership (DXCM)
| Insider Ownership | +0.26% |
|---|---|
| Institutional Ownership | +106.53% |
| Shares Outstanding | 377.36M |
| Float | 376.00M |
| Short % of Float | +4.80% |
Source: Nexqual, October 29, 2026 at 20:57 UTC.
Leadership (DXCM)
DexCom, Inc. is led by Jacob Steven Leach, President, CEO & Director, per Nexqual as of October 29, 2026 at 20:57 UTC.
| President, CEO & Director | Jacob Steven Leach |
|---|---|
| Executive Chairman of the Board | Kevin Ronald Sayer |
| Executive VP, CFO, COO & Chief Accounting Officer | Jereme M. Sylvain |
| Executive VP & CTO | Peter Simpson |
| Vice President of Finance and Investor Relations | Sean Christensen |
Major Backers & Investors (DXCM)
Notable institutional backers of DexCom, Inc. include Invesco, Baillie Gifford, Alliancebernstein L.P., according to Nexqual as of October 29, 2026 at 20:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 4.05% |
| Baillie Gifford | 3.92% |
| Alliancebernstein L.P. | 3.1% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.98% |
| Wellington Management | 2.26% |
| Fidelity | 1.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.89% |
| BlackRock | 10.13% |
| State Street | 4.87% |
| Geode Capital | 3.29% |
Source: Nexqual, October 29, 2026 at 20:57 UTC.
From DexCom, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- In July 2021, we received FDA marketing clearance for an iCGM system incorporating our Real-Time Application Programming Interfaces (API), which is an added software component that expands connectivity and interoperability of the Dexcom CGM digital ecosystem, enabling communication of iCGM data to client software intended to receive data through the cloud.
- Compatibility with mobile device applications allows for sharing glucose information with up to 10 other people for added support and care coordination. •Designed to integrate with the world's largest connected CGM ecosystem (including insulin pumps and smart insulin pens, Apple Watch, Garmin and other digital health apps).
- Dexcom Real-Time API enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases including non-medical device application, medical device data analysis, iCGM secondary display alarm, active patient monitoring, and treatment decisions.
- Real-Time API is not permitted for use in environments not currently cleared for the Dexcom CGM System (e.g., hospital inpatient care), and is not intended to be used by automated insulin delivery systems.
Legal & Regulatory Risks (Item 1A, quoted)
- Our products require multiple manufacturing processes and steps. Problems with these manufacturing processes, which may not be detectable by us in a timely manner, could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims and/or insufficient inventory, any of which could negatively impact our sales.
- We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.
- Laws and regulations governing the export of our products could adversely impact our business.
- The failure to comply with U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions could materially adversely affect our business and result in civil and/or criminal sanctions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHG | Koninklijke Philips N.V. NY Reg | USD 27.12 | ▲ 0.33% |
| GEHC | GE HealthCare Technologies Inc. | USD 76.42 | ▲ 0.79% |
| STE | STERIS plc (Ireland) | USD 232.14 | ▲ 1.47% |
| ZBH | Zimmer Biomet Holdings, Inc. | USD 97.47 | ▲ 1.12% |
| EW | Edwards Lifesciences Corporatio | USD 94.44 | ▲ 2.9% |
| BSX | Boston Scientific Corporation | USD 42.69 | ▲ 0.61% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:57 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt